Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions - Takeaways - MDSpire

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

  • By

  • Anna López-Ferrer

  • Álvaro González-Cantero

  • Ana Gutiérrez-Casbas

  • Antonio Martorell

  • Antonio Olveira

  • María Blanca Madrid-Álvarez

  • Joana Nicolau

  • Jose Manuel Carrascosa

  • Ofelia Baniandrés

  • Raquel Rivera

  • Ricardo Ruiz-Villaverde

  • Rubén Queiro

  • Pablo de la Cueva

  • April 18, 2026

  • 0 min

Share

  • 1

    Psoriasis is a systemic inflammatory disease with frequently underdiagnosed comorbidities due to fragmented care and unclear referral processes.

  • 2

    Delays in recognizing comorbidities can worsen patient outcomes, necessitating practical tools for timely identification and referral.

  • 3

    A structured, multidisciplinary approach was developed to create referral algorithms for psoriasis-associated comorbidities.

  • 4

    The project involved a literature review, focus groups, and expert consensus to establish clear referral criteria for multiple specialties.

  • 5

    These multidisciplinary pathways aim to streamline care coordination, reduce diagnostic delays, and enhance comprehensive management for psoriasis patients.

Original Source(s)

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

  • by Anna López-Ferrer, Álvaro González-Cantero, Ana Gutiérrez-Casbas, Antonio Martorell, Antonio Olveira, María Blanca Madrid-Álvarez, Joana Nicolau, Jose Manuel Carrascosa, Ofelia Baniandrés, Raquel Rivera, Ricardo Ruiz-Villaverde, Rubén Queiro, Pablo de la Cueva

  • April 18, 2026

Related Content

Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional study

The Role of SERPINA12 in Skin: Molecular Mechanisms and Its Involvement in Adipocyte Function, Psoriasis, and Palmoplantar Keratoderma

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.